Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-related resistance to infection

BMC Veterinary Research

Volumn 8, Issue , 2012, Pages

  Wilson, Stephen ^a   Greenslade, Juliet ^b   Saunders, Gillian ^a   Holcroft, Catherine ^b   Bruce, Lynn ^b   Scobey, Andy ^b   Childers, Tedd ^b   Sture, Gordon ^b   Thompson, James ^b  

^a PFIZER INC   (United States)

^b ZOETIS   (United States)

Author keywords

Feline; Leukaemia; Protection; Vaccine

Indexed keywords

ANIMALIA; FELIDAE;

CYCLINE; INACTIVATED VACCINE; P27 ANTIGEN; VIRUS ANTIGEN; VIRUS VACCINE;

AGING; ANIMAL; ARTICLE; BLOOD; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FELINE LEUKEMIA; FELINE LEUKEMIA VIRUS; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGING; ANIMALS; ANTIGENS, VIRAL; CATS; LEUKEMIA VIRUS, FELINE; LEUKEMIA, FELINE; PROLIFERATING CELL NUCLEAR ANTIGEN; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84864234769     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-8-125     Document Type: Article

References (14)

1. Hofmann-Lehmann R, Tandon R, Boretti FS, Meli ML, Willi B, Cattori V, Gomes-Keller MA, Ossent P, Golder MC, Flynn JN, Lutz H. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 2006, 24:1087-1094. 10.1016/j.vaccine.2005.09.010, 16198454.
2. Lutz H, Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lloret A, Marsilio F, Pennisi MG, Radford AD, Thiry E, Truyen U, Horzinek MC. Feline leukaemia. ABCD guidelines on prevention and management. J Feline Med Surg 2009, 11:565-574. 10.1016/j.jfms.2009.05.005, 19481036.
3. Gomes-Keller MA, Gonczi E, Grenacher B, Tandon R, Hofman-Lehmann R, Lutz H. Fecal shedding of infectious feline leukemia virus and its nucleic acids: a transmission potential. Vet Microbiol 2009, 134:208-217. 10.1016/j.vetmic.2008.08.011, 18842363.
4. Grant CK, Essex M, Gardner MB, Hardy WD. Natural feline leukemia virus infection and the immune response of cats of different ages. Cancer Res. 1980, 40:823-829.
5. Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, McDonald M, McGillivray C, Jarrett O, Neil JC, Onions DE. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol. 2001, 75:8424-8433. 10.1128/JVI.75.18.8424-8433.2001, 115087, 11507187.
6. Hoover EA, Schaller JP, Mathes LE, Olsen RG. Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated. Infect Immun. 1977, 16:54-59. 421487, 194840.
7. Harbour DA, Gunn-Moore DA, Gruffydd-Jones TJ, Caney SM, Bradshaw J, Jarrett O, Wiseman A. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine. Vaccine. 2002, 20:2866-2872. 10.1016/S0264-410X(02)00237-2, 12126896.
8. Sparkes AH. Feline leukaemia virus and vaccination. J Feline Med Surg. 2003, 5:97-100. 10.1016/S1098-612X(02)00132-8, 12670435.
9. Jarrett O, Laird HM, Hay D. Determinants of the host range of feline leukaemia viruses. J Gen Virol. 1973, 20:169-175. 10.1099/0022-1317-20-2-169, 4127732.
10. Hoover R, Fraumeni JF, Everson R, Myers MH. Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet. 1976, 1:885-887.
11. Torres AN, O'Halloran KP, Larson LJ, Schultz RD, Hoover EA. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol. 2010, 134:122-131. 10.1016/j.vetimm.2009.10.017, 2822011, 20004483.
12. Nunberg JH, Rodgers G, Gilbert JH, Snead RM. Method to map antigenic determinants recognized by monoclonal antibodies: localization of a determinant of virus neutralization on the feline leukemia virus envelope protein gp70. Proc Natl Acad Sci U S A 1984, 81:3675-3679. 10.1073/pnas.81.12.3675, 345281, 6203125.
13. Flynn JN, Hanlon L, Jarrett O. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology. 2000, 101:120-125. 10.1046/j.1365-2567.2000.00089.x, 2327065, 11012762.
14. Hofmann-Lehmann R, Holznagel E, Ossent P, Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. Clin Diagn Lab Immunol. 1997, 4:33-42. 170472, 9008278.